Zomagen Biosciences reports new NLRP3 inflammasome inhibitors
April 9, 2025
NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and neurological disorders.